Is anyone really complaining about their "big" bonuses? 2011, in terms of equity performance, and attaining goals, was spot on. They had a very successful underwritten financing, not some crap PIPE from Rodman or Roth, and the stock was added to the Russell.
I personally have no problem with the bonuses. Stimuvax is going to do what it does. PX866 has had some good early results. And they filed IND for ONT10 as planned. I am still crossing my fingers on Stimuvax, as it is just as much a crapshoot as any new therapy.
Market Data 
Markets 
AI
